The influence of recipient SLCO1B1 rs2291075 polymorphism on tacrolimus dose–corrected trough concentration in the early period after liver transplantation
Open Access
- 2 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Clinical Pharmacology
- Vol. 77 (6), 859-867
- https://doi.org/10.1007/s00228-020-03058-w
Abstract
Purpose To explore the relationship between rs2291075 polymorphism in SLCO1B1 gene, which encodes an influx transmembrane protein transporter, and tacrolimus dose–corrected trough concentration (C/D, ng ml−1 mg−1 kg−1) in the early period after liver transplantation. Methods CYP3A5 rs776746 and SLCO1B1 rs2291075 polymorphisms of 210 liver transplantation patients and their corresponding donor livers were assessed by PCR amplification and DNA sequencing. The influence of gene polymorphisms on C/D values of tacrolimus was analyzed. The early postoperative period after liver transplantation was divided into the convalescence phase (1–14 days) and stationary phase (15–28 days) according to the change of liver function and tacrolimus C/D values. Results The combined analysis of donor and recipient CYP3A5 rs776746 could distinguish the metabolic phenotype of tacrolimus into three groups: fast elimination (FE), intermediate elimination (IE), and slow elimination (SE), which was entitled the FIS classification system. Tacrolimus C/D ratios of recipient SLCO1B1 rs2291075 CT and TT carriers were very close and were significantly lower than those of recipient SLCO1B1 rs2291075 CC genotype carriers in convalescence phase (p = 0.0195) and in stationary phase (p = 0.0152). There were no statistically significant differences between tacrolimus C/D ratios of patients carried with SLCO1B1 rs2291075 CT, TT genotype donors, and those carried with SLCO1B1 rs2291075 CC genotype donors. A model consisting of tacrolimus daily dose, total bilirubin, FIS classification, and recipient SLCO1B1 rs2291075 could predict tacrolimus C/D ratios in the convalescence phase by multivariate analysis. However, recipient SLCO1B1 rs2291075 genotype failed to enter forecast model for C/D ratios in stationary phase. Recipient SLCO1B1 rs2291075 genotype had significant effect on tacrolimus C/D ratios in convalescence phase (p = 0.0300) and stationary phase (p = 0.0400) in subgroup, which excluded the interference come from donor and recipient CYP3A5 rs776746. Conclusion SLCO1B1 rs2291075 could be a novel genetic locus associated with tacrolimus metabolism. The combined analysis of donor and recipient CYP3A5 rs776746, recipient SLCO1B1 rs2291075 genotypes, could be helpful to guide the personalized administration of tacrolimus in early period after liver transplantation.Keywords
Funding Information
- Key joint fund project of National Natural Science Foundation of China and Henan Provincial Government (U1604282)
- Clinical science and technology innovation project of Shanghai ShenKang Hospital Development Center (SHDC12018X15)
- Shanghai Jiaotong University Medical Engineering Cross Research Fund (YG2017MS2)
- Clinical innovation team project of Shanghai General Hospital (CTCCR-2018BP01)
This publication has 38 references indexed in Scilit:
- Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemiaClinical Pharmacology & Therapeutics, 2015
- Intracellular sirolimus concentration is reduced by tacrolimus in human pancreatic islets in vitroTransplant International, 2015
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus DosingClinical Pharmacology & Therapeutics, 2015
- Donor IL-18 rs5744247 polymorphism as a new biomarker of tacrolimus elimination in Chinese liver transplant patients during the early post-transplantation period: results from two cohort studiesPharmacogenomics, 2015
- The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 UpdateClinical Pharmacology & Therapeutics, 2014
- Influence of TLR4 rs1927907 locus polymorphisms on tacrolimus pharmacokinetics in the early stage after liver transplantationEuropean Journal of Clinical Pharmacology, 2014
- SLCO1B1 Variants and Urine Arsenic Metabolites in the Strong Heart Family StudyToxicological Sciences, 2013
- The Impact of Sulfonylureas on Tacrolimus Apparent Clearance Revealed by a Population Pharmacokinetics Analysis in Chinese Adult Liver-Transplant PatientsTherapeutic Drug Monitoring, 2012
- Impact of interleukin-10 gene polymorphisms on tacrolimus dosing requirements in Chinese liver transplant patients during the early posttransplantation periodEuropean Journal of Clinical Pharmacology, 2011
- Intestinal Drug Transporter Expression and the Impact of Grapefruit Juice in HumansClinical Pharmacology & Therapeutics, 2007